Skip to main content

Movano’s new smart ring is focused on women’s health

Movano’s getting a week’s jump on what might well prove a banner CES for the smart ring. Today the Bay Area-based firm debuted Evie, a smart ring focused on women’s health set to hit the market later next year. The device capitalizes on the recent popularity of the unobtrusive form factor, led by the likes of Oura and Circular.

It is, however, among the first to be focused on a specific market segment (insofar as roughly 51% of the population can be considered a segment, I suppose). Women’s health certainly makes sense as a target. Companies like Fitbit and Apple have found some success with the addition of cycle tracking and related features.

That is, of course, included out of the box here. Evie’s top-level features include:

[R]esting heart rate, heart rate variability, SpO2, respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and, calories burned, sleep stages and duration, and mood tracking.

The “mood” bit here is the main selling point of the as of yet unreleased Happy Ring, which puts its data to use in hopes of helping users manage things like stress and sleep a bit better. The rest of Evie’s details are still fairly foggy — Movano is promising a better look at the product at the show next week. Of course, you can’t really blame the company for wanting to get out ahead of the scrum.

Image Credits: Movano

On top of that, Movano says it’s “planning to seek FDA clearance” for the product. Obviously no firm time line on that. It notes:

The Company plans to file for pulse oximetry metrics after having completed a successful hypoxia trial in October 2022, where accuracy for clinical SpO2 and heart rate commensurate with FDA’s consensus standard was demonstrated. While a few wearables are only FDA cleared for specific software, such as ECG and Afib, Evie is designed per regulatory standards and built in a medical device manufacturing facility that meets ISO13485 and cGMP standards. The clearance will offer women trusted and personalized insights that can help them draw connections between cause and effect, so they can better understand the “why” behind what they’re feeling. Additionally, Evie will deliver data that clinicians can deem reliable for patient care.

That’s clearly the end game for a lot of these firms, moving from the consumer space to something that’s taken a bit more seriously among medical professionals, insurance companies and the like.

“As a medical device, Evie will go beyond the status quo of other wearables on the market, and we believe it has the power to transform women’s lives and overall health,” CEO John Mastrototaro says in a release. “We are bringing together medical grade biometric data and insights in a comfortable and contemporary wearable that allows women to take ownership of their unique health journey.”

The product is expected to run around $300 and, unlike Oura, it won’t charge an additional subscription fee.

Read more about CES 2023 on TechCrunch

Movano’s new smart ring is focused on women’s health by Brian Heater originally published on TechCrunch



from TechCrunch https://ift.tt/FwhdWa3
via IFTTT

Comments

Popular posts from this blog

Max Q: Psyche(d)

In this issue: SpaceX launches NASA asteroid mission, news from Relativity Space and more. © 2023 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/h6Kjrde via IFTTT

Max Q: Anomalous

Hello and welcome back to Max Q! Last week wasn’t the most successful for spaceflight missions. We’ll get into that a bit more below. In this issue: First up, a botched launch from Virgin Orbit… …followed by one from ABL Space Systems News from Rocket Lab, World View and more Virgin Orbit’s botched launch highlights shaky financial future After Virgin Orbit’s launch failure last Monday, during which the mission experienced an  “anomaly” that prevented the rocket from reaching orbit, I went back over the company’s financials — and things aren’t looking good. For Virgin Orbit, this year has likely been completely turned on its head. The company was aiming for three launches this year, but everything will remain grounded until the cause of the anomaly has been identified and resolved. It’s unclear how long that will take, but likely at least three months. Add this delay to Virgin’s dwindling cash reserves and you have a foundation that’s suddenly much shakier than before. ...

What’s Stripe’s deal?

Welcome to  The Interchange ! If you received this in your inbox, thank you for signing up and your vote of confidence. If you’re reading this as a post on our site, sign up  here  so you can receive it directly in the future. Every week, I’ll take a look at the hottest fintech news of the previous week. This will include everything from funding rounds to trends to an analysis of a particular space to hot takes on a particular company or phenomenon. There’s a lot of fintech news out there and it’s my job to stay on top of it — and make sense of it — so you can stay in the know. —  Mary Ann Stripe eyes exit, reportedly tried raising at a lower valuation The big news in fintech this week revolved around payments giant Stripe . On January 26, my Equity Podcast co-host and overall amazingly talented reporter Natasha Mascarenhas and I teamed up to write about how Stripe had set a 12-month deadline for itself to go public, either through a direct listing or by pursuin...